Axonics, Inc. Common Stock
AXNX
AXNX was delisted on the 14th of November, 2024.
177 hedge funds and large institutions have $2.79B invested in Axonics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 77 increasing their positions, 49 reducing their positions, and 16 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
119% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 16
57% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 49
24% more capital invested
Capital invested by funds: $2.25B → $2.79B (+$546M)
12% more call options, than puts
Call options by funds: $8.46M | Put options by funds: $7.57M
11% more funds holding
Funds holding: 160 → 177 (+17)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$85.9M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$62.6M |
| 3 |
Millennium Management
New York
|
+$59.2M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$48.4M |
| 5 |
BlackRock
New York
|
+$38.8M |
Top Sellers
AXNX Hedge Fund Activity: Q2 2021 in Review
177 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Axonics, Inc. Common Stock (AXNX) for Q2 2021, worth a combined $2.79B — up 24% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new AXNX positions and 16 closed out — a net gain of 19 holders — while 77 added to existing stakes and 49 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $85.9M. The largest seller was Citadel Advisors, cutting an estimated $22.8M.
- 177 institutional investors held Axonics, Inc. Common Stock (AXNX) as of Q2 2021, up from 160 in Q1 2021.
- Funds reported $2.79B of Axonics, Inc. Common Stock stock for Q2 2021, up 24% quarter-over-quarter.
- 35 funds opened new Axonics, Inc. Common Stock positions in Q2 2021 and 16 closed out, a net change of +19 holders.
- The largest Axonics, Inc. Common Stock buyer in Q2 2021 was Fidelity Investments, an estimated $85.9M added.
- The largest Axonics, Inc. Common Stock seller in Q2 2021 was Citadel Advisors, an estimated $22.8M sold.
Based on aggregated 13F filings for Q2 2021.